A recent study published on October 8, 2025 highlights Baxdrostat, a novel oral drug that has shown promising results in patients with resistant hypertension, particularly those with chronic kidney disease
Key takeaways The most common side effects of prescription semaglutide for weight loss are gastrointestinal issues
PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes peptide-pathway variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 across 14 pathways and 150+ insights to personalize your therapy selection and dosing
Nor does it explain another surprising finding from the study: men taking these weight-loss treatments appeared to face three times the risk of vision loss compared to women
demand." "This update comes after ongoing dialogue with the FDA, and substantial efforts by Novo Nordisk to increase manufacturing capacity, including $6.5 billion dollars of investments in the U.S
